2022
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen Q, Lu L, Ma W. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers 2022, 14: 5983. PMID: 36497465, PMCID: PMC9739567, DOI: 10.3390/cancers14235983.Peer-Reviewed Original ResearchCAR T-cell therapyT-cell therapyCAR T cellsT cellsSolid tumorsChimeric antigen receptor T-cell therapyAdequate T-cell responsesCytokine release syndromeHalf of patientsT cell responsesTumor antigen targetsRelease syndromeAdoptive immunotherapyClinical efficacyHeterogeneous solid tumorsHematological malignanciesSide effectsTarget antigenAntigen targetsTherapyTumorsCancer treatmentNon-cancer cellsCancer cellsEfficacyBreast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
Yao L, Jia G, Lu L, Ma W. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Current Oncology 2022, 29: 4902-4913. PMID: 35877249, PMCID: PMC9320700, DOI: 10.3390/curroncol29070389.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyBreast cancer patientsCancer patientsEfficacy of NACHuman leukocyte antigen-DR isotypeInitiation of therapyTumor-infiltrating lymphocytesBenefits of treatmentTumor-associated macrophagesOncotype DXMolecular testingPatientsDecreased levelsCancer cellsChemotherapyTreatmentMammaPrintSurgeryLymphocytesTherapyTumorsMacrophages
2016
MNGO-11. REPORT FROM THE MENINGIOMA CONSORTIUM: CONFIRMATION OF A MENINGIOMA RISK LOCUS AT 10p12
Claus E, Calvocoressi L, Schildkraut J, Walsh K, Hansen H, Smirnov I, McCoy L, Lu L, Ma X, Bondy M, Wrensch M, Wiemels J. MNGO-11. REPORT FROM THE MENINGIOMA CONSORTIUM: CONFIRMATION OF A MENINGIOMA RISK LOCUS AT 10p12. Neuro-Oncology 2016, 18: vi103-vi103. DOI: 10.1093/neuonc/now212.432.Peer-Reviewed Original ResearchOdds ratioMeningioma riskMeningioma casesPrimary brain tumorsPopulation-based controlsCase/control studyNon-Hispanic CaucasiansAllele odds ratioGenome-wide association studiesKaiser Permanente Research ProgramSpinal cordSuch lesionsBrain tumorsControl studyConfidence intervalsFirst genome-wide association studyMeningiomasTumorsRisk lociUnited StatesSusceptibility lociRisk
2015
Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics
Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic And Obstetric Investigation 2015, 81: 169-173. PMID: 26067608, DOI: 10.1159/000431219.Peer-Reviewed Original ResearchMucinous tumorsSeromucinous tumorsOvarian tumorsComplete surgical stagingNormal-appearing appendixBorderline ovarian tumorsLymph node involvementRetrospective cohort analysisRisk of recurrenceAggressive stagingNodal diseaseSurgical stagingHazard ratioNode involvementDisease recurrencePseudomyxoma peritoneiSerous tumorsSingle institutionPathology reportsCohort analysisLower riskRecurrenceMultivariate analysisFrozen sectionsTumors